Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106454 · ClinicalTrials.gov registry record · Phase 3
Ovulation Incidence in Oral Contraceptive Users
A Phase 3 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT03106454: Completed Phase 3 study, sponsored by University of Southern California.
NCT03106454 is a Phase 3 study that has completed, run by University of Southern California. The registered enrollment target is 58 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03106454, a Phase 3 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
Since the introduction of the combined hormonal contraceptive pill, dosages of ethinyl estradiol (EE) have steadily decreased from more than 150mcg to 20mcg in an attempt to improve the risk profile associated with the COC. In 2010, the Food and Drug Administration approved a oral contraceptive pill containing EE 10mcg/NET acetate 1mg (Tradename Lo loestrin). However, no studies have compared this formulation to pills containing either higher doses of estrogen or progestin alone. It is not known whether EE 10mcg is sufficient to prevent follicular development or to support the endometrium as well as higher doses of EE. This trial addresses the question of whether an oral contraceptive pill with EE 10mcg/Norethindrone acetate 1mg will better suppress ovulation or have a better side effect profile than a progestin only pill with a nearly equal dose of norethindrone.
Primary Outcome
Ovulation based on a single serum progesterone level of 4ng/dl or greater
Interventions
- DRUG Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate
- DRUG Norethindrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-08 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 3 |
What the finished NCT03106454 record still lists
NCT03106454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate is the first listed.
NCT03106454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03106454 about?
NCT03106454 is a clinical study titled "Ovulation Incidence in Oral Contraceptive Users". Since the introduction of the combined hormonal contraceptive pill, dosages of ethinyl estradiol (EE) have steadily decreased from more than 150mcg to 20mcg in an attempt to improve the risk profile associated with the COC. In 2010, the Food and Drug Administration approved a oral contraceptive pill...
What is the current status of trial NCT03106454?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2014-08. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT03106454?
The interventions under investigation include: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate (DRUG), Norethindrone (DRUG).
Who is sponsoring clinical trial NCT03106454?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03106454's enrollment target sits among peer trials
58 1825th of 2000 higher than 174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia